Elisabeth Quoix, et al. Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article Publication
Catégorie : -other-fr
TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.
ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation
Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication
Immunotherapy for non – small – cell lung cancer: current approaches.
Elisabeth Quoix, et al. Current Respiratory Care Reports, 2014; 3 (1): 19-25 – Download the article Publication
Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.
Micaël De Meyer, et al. Journal for Immunotherapy of Cancer, 2013 – Download the article Publication
TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.
Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – Download the article Publication
Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.
Houda Boukhebza, et al. Journal of Hepatology, 2013, (58), Supplement 1, S161 – Download the article Publication
130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.
Perrine Martin, et al. Journal of Hepatology, 2013, (58), Supplement 1, S57–S58. – Download the article Publication
Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
link J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122) [Publication]
Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
link J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, J. Lee, W.K. Kang, J.O. Park, A. Pelusio, C. Breitbach, D.H. Kirn Journal of clinical Oncology, 2013, 31, (suppl; abstr 3608) [Publication]